These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14718257)

  • 21. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine.
    Rittenbach KA; Baker GB
    Drug Metab Lett; 2007 Apr; 1(2):97-100. PubMed ID: 19356027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
    Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
    Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
    Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
    Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diazinon is activated by CYP2C19 in human liver.
    Kappers WA; Edwards RJ; Murray S; Boobis AR
    Toxicol Appl Pharmacol; 2001 Nov; 177(1):68-76. PubMed ID: 11708902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
    Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
    Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450.
    Inami K; Nims RW; Srinivasan A; Citro ML; Saavedra JE; Cederbaum AI; Keefer LK
    Nitric Oxide; 2006 Jun; 14(4):309-15. PubMed ID: 16545970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19.
    Jung F; Griffin KJ; Song W; Richardson TH; Yang M; Johnson EF
    Biochemistry; 1998 Nov; 37(46):16270-9. PubMed ID: 9819219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of induction of specific hepatic cytochrome P450 isoforms in epoxidation of 4-vinylcyclohexene.
    Fontaine SM; Hoyer PB; Halpert JR; Sipes IG
    Drug Metab Dispos; 2001 Sep; 29(9):1236-42. PubMed ID: 11502734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.
    Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Unadkat JD
    Br J Clin Pharmacol; 2014 Mar; 77(3):554-70. PubMed ID: 23834474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
    Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.
    Aitken AE; Lee CM; Morgan ET
    Free Radic Biol Med; 2008 Mar; 44(6):1161-8. PubMed ID: 18206661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6.
    Dicke KE; Skrlin SM; Murphy SE
    Drug Metab Dispos; 2005 Dec; 33(12):1760-4. PubMed ID: 16174803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Membrane integration of recombinant human P450 forms.
    Shukla A; Huang W; Depaz IM; Gillam EM
    Xenobiotica; 2009 Jul; 39(7):495-507. PubMed ID: 19534586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.
    Reynald RL; Sansen S; Stout CD; Johnson EF
    J Biol Chem; 2012 Dec; 287(53):44581-91. PubMed ID: 23118231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models.
    Gleeson MP; Davis AM; Chohan KK; Paine SW; Boyer S; Gavaghan CL; Arnby CH; Kankkonen C; Albertson N
    J Comput Aided Mol Des; 2007; 21(10-11):559-73. PubMed ID: 18034311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.